EP1207903A1 - Reduction de l'immunogenicite de greffons non humains - Google Patents
Reduction de l'immunogenicite de greffons non humainsInfo
- Publication number
- EP1207903A1 EP1207903A1 EP00959076A EP00959076A EP1207903A1 EP 1207903 A1 EP1207903 A1 EP 1207903A1 EP 00959076 A EP00959076 A EP 00959076A EP 00959076 A EP00959076 A EP 00959076A EP 1207903 A1 EP1207903 A1 EP 1207903A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- tissue
- macrophages
- complement
- porcine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000282414 Homo sapiens Species 0.000 title claims description 79
- 230000005847 immunogenicity Effects 0.000 title claims description 9
- 230000009467 reduction Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 243
- 210000002540 macrophage Anatomy 0.000 claims abstract description 79
- 230000000295 complement effect Effects 0.000 claims abstract description 60
- 230000001537 neural effect Effects 0.000 claims abstract description 43
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 238000002054 transplantation Methods 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000001605 fetal effect Effects 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 15
- 230000005593 dissociations Effects 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 11
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 27
- 229940088598 enzyme Drugs 0.000 claims description 14
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 229940119679 deoxyribonucleases Drugs 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims 2
- 230000002025 microglial effect Effects 0.000 abstract description 27
- 210000004958 brain cell Anatomy 0.000 description 64
- 239000002953 phosphate buffered saline Substances 0.000 description 53
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 52
- 210000001519 tissue Anatomy 0.000 description 50
- 239000002609 medium Substances 0.000 description 40
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 39
- 238000010186 staining Methods 0.000 description 39
- 241000282898 Sus scrofa Species 0.000 description 36
- 210000001744 T-lymphocyte Anatomy 0.000 description 35
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 description 31
- 210000001130 astrocyte Anatomy 0.000 description 29
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 238000000684 flow cytometry Methods 0.000 description 25
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 22
- 210000004698 lymphocyte Anatomy 0.000 description 22
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 21
- 239000012894 fetal calf serum Substances 0.000 description 21
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 20
- 239000003656 tris buffered saline Substances 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 17
- 210000005013 brain tissue Anatomy 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 239000006285 cell suspension Substances 0.000 description 15
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000002257 embryonic structure Anatomy 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 11
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108090001090 Lectins Proteins 0.000 description 10
- 102000004856 Lectins Human genes 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 102000013415 peroxidase activity proteins Human genes 0.000 description 9
- 108040007629 peroxidase activity proteins Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 239000013504 Triton X-100 Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 7
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000009696 proliferative response Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102100032912 CD44 antigen Human genes 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000001259 mesencephalon Anatomy 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000008763 Neurofilament Proteins Human genes 0.000 description 4
- 108010088373 Neurofilament Proteins Proteins 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108010034949 Thyroglobulin Proteins 0.000 description 4
- 102000009843 Thyroglobulin Human genes 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 210000005044 neurofilament Anatomy 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229960002175 thyroglobulin Drugs 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000002403 aortic endothelial cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011072 cell harvest Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000004002 dopaminergic cell Anatomy 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 101150047145 algG gene Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005188 flotation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 229960001407 sodium bicarbonate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010408 sweeping Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960001814 trypan blue Drugs 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 101000863717 Bos taurus Deoxyribonuclease-1 Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000869693 Homo sapiens Protein S100-A9 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 241000738583 Senna artemisioides Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- -1 hexamycin Chemical compound 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N n-(3,4,5,6-tetrahydroxy-1-oxohexan-2-yl)acetamide Chemical compound CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to a transplantation material produced by dissociation of porcine tissue and removal of macrophages and/or rnicroglial cells therefrom.
- the tissue could be an embryonic or fetal neural tissue and the removal could be effected by exposing the preparation above to antibodies against the Gal ⁇ l-3Gal ⁇ l-R epitope and a complement reagent.
- the invention also relates to the use of such a transplantation material for preparing a pharmaceutical preparation useful when transplanting neural tissue.
- the invention also relates to a kit comprising one or more enzymes for tissue dissociation, an antibody preparation and a complement reagent.
- the invention also relates to a process for removal of macrophages and/or rnicroglial cells from porcine embryonic or fetal neural tissue. Finally, the invention relates to a process for treatment of neurological disorders with such pretreated porcine neural grafts.
- Neural transplantation is a potential therapy for Parkinson's and Huntington's diseases (Peschanski et al., 1995; Olanow et al, 1997; Borlongan et al, 1999; Dunnett and Bj ⁇ rklund, 1999). Due to the short supply of human donor material (Dunnett and Bj ⁇ rklund, 1999), tissue derived from an animal source is considered an appropriate alternative (Isacson and Breakefield, 1997; Edge et al., 1998), and has the advantage of being genetically modifiable (Cozzi and White, 1995; Zawada et al, 1998).
- ventral mesencephalic tissue from pig embryos can grow anatomically correct connections (Isacson et al., 1995) and restore induced behavioural deficits (Huffaker et al., 1989; Galpern et al., 1996). So far, porcine neural tissue has been grafted to 12 Parkinson and 12 Huntington patients in small-scale safety trials (Edge et al., 1998).
- Porcine neural grafts are, however, prone to immune-related rejection in the human brain (Deacon et al, 1997). Rejection of murine neural grafts can be prevented by treatment of rat hosts with antibodies against T lymphocytes of the immune system (Okura et al., 1997).
- the human T-cell repertoire includes cells that are activated by porcine major histocompatibility complex (MHC) antigens on porcine cells (direct recognition), and cells that are activated by peptides derived from porcine proteins after processing and presentation by human antigen presenting cells (indirect recognition) (Satake et al., 1994; Dorling et al., 1996).
- MHC major histocompatibility complex
- the porcine donor cells For direct recognition to occur, the porcine donor cells must express class I and/or class II MHC antigens, which are recognised by CD8 and CD4 T lymphocyte cells, respectively. Survival of human neural tissue in mouse brain can be prolonged by depletion of host CD4, but not CD8, T cells (Wood et al., 1996), proving that CD4 T cells are essential for neural xenograft rejection, which is also the case for rejection of non-neural xenografts (Pierson et al., 1989; Kaufman et al, 1995; Korsgren, 1997).
- pig MHC class II antigens In vitro, pig MHC class II antigens elicit a much stronger proliferative response in human T cells than pig MHC class I antigens (Kirk et al., 1993; Kumagai-Braesch et al, 1993; Yamada et al., 1995; Dorling et al., 1996), suggesting that cells which express MHC class II antigens, or have the potential to express these molecules once implanted, contributes heavily to the immunogenicity of the donor tissue. MHC class II antigens have not been reported to occur on neurons (Lampson, 1995).
- Cyclosporin an immunosuppressant that inhibits alloreactivity, is inadequate at protecting porcine xenografts from immune attack in rats (Wennberg et al., 1995).
- Continuous cyclosporin treatment of rats hosting porcine neural grafts resulted in some degree of graft survival in 74% of the animals 3-4 months after transplantation (Pakzaban et al., 1995).
- a Parkinson patient that received porcine neural grafts and continuous cyclosporin treatment had poorly surviving grafts 7.5 months after transplantation, considering that 1.2 x IO 7 cells were implanted and only 638 dopaminergic cells were present at postmortem histology (Deacon et al., 1997).
- WO9637602 Al relates to the use of hepatocytes to treat subjects with disorders characterised by insufficient liver function. Methods are disclosed in order to make these hepatocytes less immunogenic, especially by masking certain antigens, in particular MHC class I antigen.
- WO9636358 Al relates to reagents and methods in order to inhibit antibody-mediated xenograft rejection by xenogeneic transplant recipients.
- the object is to block antigen on endothelial cells of the donor organ i e cells being the donor cells at first brought in contact with the blood of the recipient.
- This document only relates to antibody- mediated immunity and the inhibition thereof by using anti-donor antibodies, whereas the present invention relates to the removal of a specific cell population from a neural cell mixture in order to make it less prone to stimulate the T cells of the recipient.
- the Gal epitope is only mentioned as a possible antigen to block.
- Claim 1 of WO9636358 Al is very broad and relates to the mhibition of all possible xenogeneic antigens.
- the largest difference compared to the process according to the present invention is that the latter relates to depletion of macrophages and/or rnicroglial cells via the Gal epitope and not to blocking thereof.
- a potential target according to the invention is the carbohydrate epitope, Gal ⁇ l-3Gal ⁇ 1-R ( ⁇ -galactosyl epitope), which the inventors have now demonstrated on macrophages and/or rnicroglial cells and endothelial cells, but not on neurons and astrocytes, in embryonic pig brain (Sumitran et al., 1999).
- Human serum contains a high titer of naturally occurring, complement-activating IgG and IgM antibodies against the ⁇ -galactosyl epitope (anti-Gal) (Galili, 1993; Rother and Squinto, 1996), but also antibodies against other epitopes expressed in ventral mesencephalon of pig embryos (Sumitran et al., 1999).
- Purified anti-Gal and complement may, therefore, have the ability to selectively lyse macrophages and/or rnicroglial cells and endothelial cells, and remove these cells from dissociated porcine neural tissue prior to transplantation, for the treatment of neurological disorders.
- neural xenograft survival is compromised by host CD4 T lymphocytes.
- porcine embryonic brain tissue which is of interest as donor material in therapeutic xenografting for Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, stroke, pain, and spinal cord injuries
- the possibility of using the ⁇ -galactosyl epitope as target for antibody- and complement-mediated removal of macrophages and/or rnicroglial cells has been studied in vitro by the inventors.
- porcine embryonic brain cells treated with purified human anti-Gal and rabbit complement contained 0.8% macrophages and/or rnicroglial cells and did not induce proliferation of human CD4 T cells, while brain cells given a control treatment with medium and rabbit complement contained 3.4% macrophages and/or rnicroglial cells and induced a significant proliferative response in human CD4 T lymphocytes.
- One object of the invention is a transplantation material, characterised in that it has been produced by (a) dissociation of porcine embryonic or fetal neural tissue,
- step (b) removal of macrophages and/or rnicroglial cells by exposing the preparation of step (a) to antibodies against the Gal ⁇ l-3Gal ⁇ 1-R epitope and a complement reagent.
- Dissociation of a tissue could be either partial or full.
- Partial dissociation means dissociation of tissue into a suspension containing cell aggregates.
- Full dissociation means dissociation of tissue into a single-cell suspension. It is preferred that the partial or full dissociation is effected by the use of one or more enzymes such as proteases and/or deoxyribonucleases. Some examples of such enzymes are given by Barker et al. (1995) such as bovine trypsin from Worthington Biochemical Corporation. Another suitable enzyme is porcine trypsin, type IX, from Sigma. Some examples of media for washing the dissociated tissue are given by Watts et al. (1998) such as Dulbecco's modified Eagle ' s medium (DMEM).
- DMEM Dulbecco's modified Eagle ' s medium
- Phosphate buffered saline could also be used. It is also preferred that the complement reagent is rabbit serum or complement purified from rabbit serum.
- examples of antibodies according to the invention are monoclonal or polyclonal antibodies. The antibodies may derive from any species, but are preferably human. The term monoclonal antibody is art-recognised terminology. Monoclonal antibodies of the present invention can be prepared according to general methods as described in Kohler et al., 1975. Polyclonal antibodies can, e.g., be purified from animal or human serum. There is also a possibility to create new molecules that binds to the epitope by means of computer simulation. Methods for computer simulation are known by a person skilled in the art, e.g., as described in EP 0660 210 A2.
- the antibodies according to the invention bind to Gal ⁇ l-3Gal ⁇ 1-R-terminated epitopes.
- An example of such an epitope is the Gal ⁇ l-3Gal ⁇ l-4GlcNAc-R epitope.
- the Gal ⁇ l-3Gal ⁇ l-R antigen and the isolation thereof is described in Subcellular Biochemistry, Vol. 32: alpha-Gal and Anti-Gal, edited by Galili and Avila. Kluwer Academic/Plenum Publishers, New York, 1999; Liu et al. (1 97); and Hallberg et al. (1998).
- Another object of the invention is the use of the above-mentioned transplantation material for preparing a pharmaceutical preparation which is useful when transplanting neural tissue.
- kits for use in treating a porcine tissue in order to reduce its immunogenicity, characterised in that it comprises one or more enzymes for tissue dissociation, a preparation of an antibody against the Gal ⁇ l-3Gal ⁇ l-R epitope, and a complement reagent.
- the antibody is a polyclonal antibody. It is especially preferred that the antibody is of human origin. It is also preferred that the antibody binds to macrophages and/or rnicroglial cells. Examples of enzymes and complement reagents are given above.
- Another object of the invention is a process for removal of macrophages and/or rnicroglial cells from porcine embryonic or fetal neural tissue, characterised in that
- step (b) the macrophages and/or rnicroglial cells are depleted from the preparation of step (a) by exposing the preparation in step (a) to the antibody coupled to a carrier or by flow sorting, or
- step (c) the macrophages and/or rnicroglial cells are depleted from the preparation of step (a) by treating the preparation of step (a) with a complement reagent.
- porcine embryonic or fetal neural tissue is dissociated by the use of one or more enzymes such as proteases and/or deoxyribonucleases.
- the antibody is a polyclonal antibody such as an antibody of human origin.
- the complement is rabbit serum or complement purified from rabbit serum. Examples of suitable carriers are paramagnetic beads or a plastic surface.
- Another object of the invention is a process for treatment of neurological disorders, characterised in that (a) porcine embryonic or fetal neural tissue is dissociated, (b) the dissociated tissue is treated with antibodies against the Gal ⁇ l-3Gal ⁇ l-R epitope and a complement reagent in order to remove macrophages and/or rnicroglial cells,
- the disorders are selected from the group consisting of Parkinson's disease, Huntington ' s disease, multiple sclerosis, epilepsy, stroke, pain, and spinal cord injuries.
- the inventors propose that the dissociated tissue should be pretreated with anti-Gal and complement, the effect of which is shown in Figure 12. If the pretreatment with anti- Gal and complement can enhance survival of porcine neural grafts in humans, it may serve as a simple and inexpensive way of reducing donor tissue immunogenicity prior to clinical neural xenotransplantation.
- Figure 1 Flow cytometric analysis of unstained brain cells from 28-day-old pig embryos.
- FIG. 1 Expression of CD 18, CD56, CD44, CD4, and GFAP by cells isolated from 28-day-old embryonic pig brains and grown for 14 days in primary culture.
- Figure 4 Flow sorted astrocyte and macrophage rnicroglial populations, separated on the basis of CD56 expression.
- FIG. 1 Western blot analysis of BS-IB4 reactive, solubilized glycoprotein isolated from cell membranes.
- FIG. 7 Saggital section of the ventral mesencephalon of a 27-day-old pig embryo stained immunohistochemically for tyrosine hydroxylase.
- Figure 8 Expression of the ⁇ -galactosyl epitope on cultured porcine embryonic brain cells.
- Figure 9 Effect of human serum and rabbit complement on cultured and freshly isolated porcine embryonic brain cells.
- Figure 10 Reactivity towards the ⁇ -galactosyl epitope of the antibodies purified from normal human serum using porcine thyroglobulin.
- Figure 11 Proliferative response of CD4 T lymphocytes from two human individuals when co-cultured with pretreated porcine embryonic brain cells.
- Figure 12 Summary of the effect of anti-Gal and complement on dissociated porcine brain tissue in the clinical situation and in an in-vitro model.
- Figure 13 Effect of the pretreatment on porcine neural graft function in a rat model of Parkinson's disease.
- Figure 14 Histology of a graft derived from porcine embryonic VM tissue pretreated with anti-Gal and complement.
- ⁇ -galactosyl epitope means Gal ⁇ l-3Gal ⁇ l-R (where R is the rest of the molecule), anti-Gal means antibodies against Gal ⁇ l-3Gal ⁇ 1-R (where R is the rest of the molecule),
- BSA bovine serum albumin
- DMEM Dulbecco's modified Eagle ' s medium
- EDTA means ethylenediaminetetraacetic acid
- FCS means fetal calf serum
- FITC fluorescein isothiocyanate
- FBS means fetal bovine serum
- Gal D-galactose
- GlcNAc means D-N-acetylglucosamine
- lg immunoglobulin
- mAb means monoclonal antibody
- PBS phosphate buffered saline
- PMSF phenylmethane sulfonyl fluoride
- PLMEC porcine liver microvascular endothelial cell
- RPE R-phycoerythrin
- TBS Tris-buffered saline
- TH tyrosine hydroxylase
- TNF tumour necrosis factor
- VCAM vascular cell adhesion molecule
- VM ventral mesencephalon.
- Brain cells were isolated from whole brain or ventral mesencephalon of 28, 35, 42, and 56 days old pig fetuses (Table 1). Brains isolated from each of the 12 litters of 6-15 fetuses were pooled in Gey's Balanced Salt Solution (Life Technologies, Scotland) and meninges were carefully removed.
- brains were cut into small pieces, transferred to brain-cell medium (Eagle's Minimum Essential Medium with Earle's Salts supplemented with L-glutamine, amino acids, vitamins (all Life Technologies), penicillin, hexamycin, and sodium bicarbonate) with 20% heat- inactivated (56°C, 30 min) horse serum (Life Technologies), triturated with a flame- polished pipette, and finally filtered through a Nitex filter with 80- ⁇ m pores. The filtrates were diluted in brain-cell medium with 20% horse serum to give total volumes of 10, 20, 30, or 50 ml per 28, 35, 42, or 56 days old brain, respectively.
- brain-cell medium Eagle's Minimum Essential Medium with Earle's Salts supplemented with L-glutamine, amino acids, vitamins (all Life Technologies), penicillin, hexamycin, and sodium bicarbonate
- horse serum Life Technologies
- the filtrates were diluted in brain-cell medium with 20% horse serum to give total volumes of 10, 20, 30, or 50 ml per 28, 35, 42,
- the brain cells were analysed directly after isolation or after 12-14 days in primary culture. Cultures were prepared by adding 5.0 ml cell suspension, prepared as described above, to poly-D-lysine (Sigma, USA) coated culture flasks (50-ml flasks; Nunc, Denmark), followed by incubation at 37°C in a humidified atmosphere of 5% C0 2 in air. After 2 days, when the cells had attached, the medium was changed to brain-cell medium with 20% horse serum, and subsequently twice a week to brain-cell medium with 10% horse serum.
- the cultured brain cells were detached by gently sweeping the bottoms of the culture flasks with a plastic pipette (culture flasks were checked by microscopy to ensure that all cells had detached), transferred to V-bottomed tubes (content of one flask to one tube) and centrifiiged (100 g, 10 min).
- the supematants were discarded, each tube was given either 500 ⁇ l or 500 ⁇ l lymphocyte medium and the cells were resuspended using a syringe with a needle of 0.5 mm internal diameter.
- the tubes were left for 15 min at room temperature to sediment cell clusters, and the supematants with single cells in suspension were harvested and used for subsequent analyses.
- mice anti- MHC I IgG a immunofluorescence staining of the brain cells
- mouse anti-MHC II IgG 2a immunofluorescence staining of the brain cells
- mouse anti-pig CD4 IgG 2a 1: 1; clone PT90A; VMRD
- mouse anti-pig CD44 IgG 2a 1: 1; clone PORC24A; VMRD
- mouse anti-human CD 18 IgGj FITC (1:1; clone MHM23; DAKO, Denmark
- mouse anti-human CD56 IgGj RPE 1:1; clone MY31; BD
- Goat anti-mouse immunoglobulins F(ab') 2 RPE (1:10; DAKO) was used as secondary reagent for the MHC antibodies and the antibodies against CD4 and CD44.
- Swine anti-rabbit immunoglobulins FITC (1:10; DAKO) was used as secondary antibody for the GFAP antibody.
- Samples exposed to species- and isotype-matched irrelevant antibody mouse IgG a negative control (1: 1; DAKO) or mouse IgG, negative control FITC/RPE/Cy5 (1: 1; DAKO)
- secondary antibody only were used as negative controls. According to the manufacturers, primary antibodies against antigens from other species than pig cross-reacted strongly with the corresponding pig antigens. Higher concentrations of antibodies than indicated did not give stronger staining. Staining reagents for demonstration of phagocytosis are given below.
- the cells Prior to staining for GFAP, the cells were fixed and permeabilized in the Falcon tubes by incubating them for 10 min in 2.0 ml FACS Lysing Solution (BD). and subsequently for 10 min in 0.5 ml FACS Permeabilizing Solution (BD).
- BD FACS Lysing Solution
- the punty of the cell sorted populations was determined by flow cytometry without further staining of the cells
- the viability of the macrophages/microglial cells was determined by flow cytometry after staining with propidium iodide
- the viability of the astrocytes was determined by counting the blue cells and the total number of cells, 10 mm after mixing aliquots of 0 4% trypan blue solution (Sigma) and cell suspension Mixed lymphocyte-brain cell culture.
- Mononuclear blood cells (lymphocytes and monocytes) from 3 healthy blood donors (H-3970, H-3977. and H-8053) were isolated from buffy coats by flotation and cryopreserved as earlier described (Brevig et al., 1997). Prior to use.
- lymphocyte medium 90% RPMI 1640 with HEPES, 10% heat-inactivated FCS, 100 IU/ml penicillin, 100 ⁇ g/ml streptomycin, and 2.0 mM L-glutamine; all Life Technologies) at 37°C in a humidified atmosphere of 5% C0 2 in air. Volumes of 100 ⁇ l lymphocyte medium containing 2. Ox 10 5 human mononuclear blood cells (responders) were dispensed in wells of U-bottomed microtiter plates (Nunc).
- Unseparated brain cells, sorted brain cells, and allogeneic mononuclear blood cells (stimulators) were ⁇ -irradiated (50 Gy), and 2.0 ⁇ l0 4 cells in 100 ⁇ l lymphocyte medium were added to wells with responders (3 or 5 wells per combination). Wells receiving responders and lymphocyte medium but no stimulators were used as negative controls (5 or 12 wells per combination). Each well was given 1.0 ⁇ Ci [ 3 H]-thymidine (Amersham. UK) 24 h prior to cell harvest.
- PLMECs Porcine liver microvascular endothelial cells
- the cell suspension was filtered to remove undissociated tissue, washed three times with PBS, and cultured for 1 week in 0.2% gelatin-coated 25 cm 2 flasks (Falcon, USA) using the medium indicated below. Expanded cells were activated for 18 h with 100 U/ml human recombinant TNF- ⁇ (Genzyme.
- Ventral mesencephalic (VM) regions were obtained from E26-27 pig embryos of the Pigham strain (derived from a cross between Swedish Landrace x Yorkshire sows and Hampshire boars; Nyholms Breeding Farm, Sweden). Pigs were bred and euthanized according to local and national animal ethics regulations.
- the VM cells contained approximately 10-15% dopaminergic cells, the rest being other neurons, glia, and endothelial cells.
- the tissue was dissected in Hank's balanced salt solution with 0.3 ⁇ M lazaroid U-83836E
- VM tissue specimen about 2 x 2 x 1 mm was cut into 4-6 smaller pieces, and these were transfened to cold storage medium (Grasbon-Frodl et al., 1996) and shipped to Huddinge Hospital for analysis the same or the following day. The tissue was then triturated into a cell suspension by several passages through a pipette. Prior to shipping and in vitro analysis, the viability was checked using ethidium bromide. Flow cytometnc assays.
- ⁇ - galactosyl epitope expression was estimated by incubating VM cells or PLMECs with biotinylated Bandereia Simplicifolia isolectin B4 (4 ⁇ g/ml; cat.no. L-2140; Sigma) followed by detection with FITC-conjugated avidin (cat.no. 55880; Organon Teknika, USA) diluted 1:2000 in 1 % BSA PBS. Alternatively, 200 ⁇ l of rabbit serum (cat. no. 439665.
- the latter antibody binds rnicroglial cells and crossreacts with the porcine antigen (Serotec).
- the VectastainTM standard peroxidase ABC kit was used (Vector Labs).
- BS-IB4 isolectin Bandereia Simplicifolia IB4
- sections were treated with a 3% H2 ⁇ 2/10% methanol solution to block endogenous peroxide activity, followed by a 1 h incubation in 1% BSA blocking solution.
- An equal volume of solubilized cell membrane proteins and 2 x reducing sample buffer were mixed and applied onto the gel.
- SDS-PAGE and Western blotting were mn by the method of Laemmli (Laemmli et al., 1970) with 5 % stacking gels and 8 % resolving gels using a vertical Mini-PROTEAN II electrophoresis system (Bio-Rad, USA). Separated proteins were electrophoretically blotted onto HybondTM-C extra membranes (Amersham, UK) using a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad). Protein gels were stained using a silver staining kit according to the instructions of the manufacturer (Bio-Rad).
- Example 4-7 Also for Example 1-3 unless specified otherwise.
- the memnges were removed, and the brains from each litter were pooled and cut into small pieces, which were transfened to brain-cell medium (Eagle's minimum essential medium with Earle's salts supplemented with heat-inactivated (56°C, 30 min) fetal calf serum (FCS), L-glutamine, amino acids, vitamins, penicillin, streptomycin, and sodium bicarbonate (all Life Technologies Inc., USA)).
- FCS fetal calf serum
- L-glutamine L-glutamine
- amino acids amino acids
- vitamins penicillin, streptomycin, and sodium bicarbonate
- Bandereia Simplicifolia isolectin staining of porcine embryonic brain cells Suspended and adherent, cultured porcine embryonic brain cells were stained with Bandereia Simplicifolia isolectin B4 (BS-IB4) in order to determine the expression of the ⁇ - galactosyl epitope by flow cytometry and light microscopy, respectively.
- Suspensions of 5.0xl0 5 brain cells in 100 ⁇ l PBS were incubated with or without 3.0 ⁇ g FITC- conjugated BS-IB4 (Sigma) at 4°C for 30 mm, washed twice in PBS (250 g, 5 min), and analysed by flow cytometry as described below.
- Brain cells adherent to a culture dish were fixed in 4% paraformaldehyde in PBS for 30 min, permeabilized by 1% Triton X-100 (Sigma) in Tris-buffered saline (TBS) for 15 min, and stained by incubation with biotinylated BS-IB4 (100 ⁇ g/ml TBS; Sigma) for 60 min, peroxidase- conjugated streptavidin (1 :200 in TBS; DAKO, Denmark) for 60 min, and finally 0.05% 3 ; 3'-diaminobenzidine (DAB; Sigma) in TBS for 15 min. Between the incubations, which were all at 20°C, the cells were thoroughly rinsed with TBS. After incubation with DAB, the cells were rinsed with TBS and distilled water, covered with Aquamount (BDH Laboratory Supplies, UK), and examined in an inverted light microscope.
- Triton X-100 Sigma
- TBS-IB4 Tris-buffered s
- porcine embryonic brain cells Treatment of porcine embryonic brain cells with human serum and rabbit complement.
- Freshly isolated porcine embryonic brain cells were split into three aliquot suspensions (3.0 ⁇ l0 6 cells in 2.0 ml PBS), of which one received a treatment with human semm and rabbit complement: the cells were given 8.0 ml heat-inactivated human semm (pooled from blood type AB donors), incubated for 60 min at 4°C, washed in cold PBS (400 g, 5 min), resuspended in 5.0 ml Low-Tox-M rabbit complement (lyophilised content of one vial was reconstituted to 10 ml with PBS; Cedarlane Laboratories Ltd., Canada), incubated for 60 min at 37°C, and finally washed in PBS (400 g, 5 min).
- the three cell suspensions were cultured for 10 days in separate culture flasks as described above, and cells from one culture flask, not treated prior to culture, then received an identical treatment with human semm and rabbit complement. Cells from all three cultures were analysed by flow cytometry without prior staining, to deterrriine the content of autofluorescent macrophages/microglial cells.
- CD4 T lymphocytes Isolation of human CD4 T lymphocytes.
- Mononuclear cells lymphocytes and monocytes
- monocytes and monocytes Mononuclear cells from two healthy blood donors were isolated from buffy coats by flotation as earlier described (Brevig et al, 1997), cooled on ice for a few minutes, and mixed with washed, paramagnetic Dynabeads M-450 CD4 (Dynal. Norway) to a bead-to-cell ratio of 0.6.
- the tubes were incubated head-over-tail at 4°C for 40 min and left in a magnetic particle concentrator (MPC; Dynal) for 3 min.
- MPC magnetic particle concentrator
- the supematants were discarded, and the positively isolated cells on the beads were washed five times in PBS with 2% FCS and resuspended in Detachabead CD4/CD8 reagent (1.0 ⁇ l per 2.8 10 beads; Dynal). After incubation head-over-tail at 20°C for 50 min, the tubes were given 5 ml PBS with 2% FCS and left for 3 niin in the MPC. The positively isolated cells in the supematants were transfened to ne ⁇ v tubes and washed, in PBS with 2% FCS, once with the MPC and once by centrifugation (500 g, 10 min).
- the purity of the isolated CD4 T lymphocytes was analysed by flow cytometry after incubating 5.0x 105 cells in 100 ⁇ l PBS with 10 ⁇ l mouse anti-human CD3/4 FITC/RPE (Becton Dickinson, USA) at 4°C for 30 min and washing twice in PBS (250 g, 5 min). Isolated cells from individual A and B contained 99.1% and 99.7% double-positive cells, respectively.
- Human IgG, IgM, and anti-Gal were diluted in lymphocyte medium just prior to use. After 60 min at 4°C, the cells were washed in cold lymphocyte medium (400 g, 5 min) and resuspended in 1.0 ml Low-Tox-M rabbit complement (lyophilised content of one vial was reconstituted to 10 ml with lymphocyte medium). After 60 min at 37°C, the cells were washed (400 g, 5 min), resuspended in lymphocyte medium, and counted. About 15% of the brain cells were lost in the incubation and centrifugation steps.
- the cells were ⁇ -irradiated (40 Gy), and 2.0 ⁇ IO 4 brain cells in 100 ⁇ l lymphocyte medium were dispensed in wells of round-bottomed, 96-well plates (Nunc). Volumes of 100 ⁇ l lymphocyte medium containing 2. Ox IO 3 human CD4 T lymphocytes were added in triplicate to wells with brain cells. Wells receiving CD4 T cells and lymphocyte medium but not brain cells were used to determine the background proliferative activity of the CD4 T cells. Each well was given 1.0 ⁇ Ci [ ⁇ ]thymidine (Amersham, UK) 24 h prior to cell harvest. After 3-7 days of incubation at 37°C in a humidified atmosphere of 5% C0 2 in air, cells were harvested onto glass fibre filters and counted for 15 min in a 1450 MicroBeta Trilux ⁇ -counter (Wallac, Finland).
- the brain-cell suspensions were analysed by flow cytometry without prior staining and after staining with propidium iodide (1.0 ⁇ g/ml PBS; Sigma) to determine the relative number of macrophages/microglial cells and viable cells, respectively. Samples given propidium iodide were analysed after 10 min in the dark at room temperature.
- FACSort flow cytometer (Becton Dickinson). A forward-scatter threshold was set to exclude subcellular debris.
- Example 8 See also for Example 4-7 and Example 4 itself.
- brain cells were detached and dissociated, washed (100 g, 10 min), and resuspended in phosphate-buffered saline (PBS, pH 7.4) with 2% FCS.
- PBS phosphate-buffered saline
- FCS phosphate-buffered saline
- Purification of anti-Gal from human serum As in Example 4 but only purification of human anti-Gal from semm pooled from more than 20 healthy, blood type AB donors using beaded agarose with porcine thyroglobulin (Sigma).
- Human CD4 T lymphocytes were isolated from buffy coats of two healthy blood donors using Dynabeads M-450 CD4 (Dynal, Norway) and the conesponding Detachabead reagent (Dynal), as described (Brevig et al., 1997). The purity was analysed by flow cytometry after staining with mouse anti- human CD3/4 FITC/RPE (Becton Dickinson). Cells isolated from individual A and B contained 99.1% and 99.7% double-positive cells, respectively. Volumes of 100 ⁇ l medium containing 2.0 x 10 5 human CD4 T cells were added in triplicate to wells with brain cells or medium only.
- Ventral mesencephalon was dissected from 27-day-old pig embryos of crown-rump length 19-21 mm. Tissue pieces from 16 embryos were pooled in 5.0 ml Dulbecco's modified Eagle medium (DMEM, cat. no. 41966-011; Life Technologies, Scotland) containing 0.1% porcine trypsin, type IX (cat. no. T-0134; Sigma) and 0.05% bovine deoxyribonuclease I, type IV (cat. no.
- DMEM 500 ⁇ g/ml
- 600 ⁇ l DMEM only control
- the cell suspensions were washed in DMEM (200 g, 5 min), resuspended in 5.0 ml DMEM containing Low-Tox-M rabbit complement (lyophilized content of one vial was reconstituted to 10 ml, cat. no. CL3051; Cedarlane, Canada), and incubated for another 60 min at 37°C.
- the cells were then washed in DMEM (200 g, 5 min) and resuspended in DMEM to a concentration of 1.4 x IO 5 cells/ ⁇ l.
- Anti-Gal-pretreated and control- pretreated cell suspensions contained 90% and 92% viable cells (trypan-blue negative), respectively.
- Unilateral lesions of the dopaminergic nigrostriatal pathways were produced by injecting 4.0 ⁇ l sterile saline containing 32 mM 6-hydroxydopamine HC1 (Sigma) and 1.0% ascorbate at 1.0 ⁇ l min at the following coordinates relative to bregma and dura mater, posterior 2.8 mm, right 2.0 mm, and ventral 8.4 mm.
- Temgesic buprenorphinum 0.10 mg/kg, i.m.; Reckitt & Colman, UK
- Intrastriatal transplantation Seven weeks after injection of 6-hydroxydopamine, rats received 3.0 ⁇ l DMEM with anti-Gal -pretreated or control-pretreated VM cells at 1.0 ⁇ l/min at the following coordinates relative to bregma and dura mater, anterior 0.7 mm, right 2.6 mm, and ventral 4.7 mm (toofhbar set at 2.5 mm below the interaural line). Animals were anesthetized and pain relieved as described above. Rotational response to D-amphetamine sulphate was assessed 3. 7, and 10 weeks posttransplantation, as described above, and Mann- Whitney statistical tests (p - 0.03) were performed for each time point (two-tailed ? values were estimated using the z statistic).
- Tris-buffered saline TBS, pH 7.4
- Triton X-100 mouse anti-cow neurofilament-70 IgGi (1: 1000; clone DP.5.112; purchased from Dr. L. Soriano, France (soriag@aol.com)), polyclonal rabbit anti-rat tyrosine hydroxylase (1:250; Pel- Freez Biologicals, USA), or mouse anti-rat CD45 IgGj (1 : 100; clone MRC OX-l; Serotec, UK).
- the neurofilament and tyrosine-hydroxylase antibodies are known to crossreact with their respective porcine antigens, but the neurofilament antibody does not react with rodent neurofilament.
- the sections were incubated with biotinylated sheep anti-mouse lg (1:200 in TBS with 1% Triton X-100; Amersham) or biotinylated donkey anti-rabbit lg (1:200 in TBS with 1% Triton X-100; Amersham) for 60 min at 20°C, rinsed 3 x 15 min in TBS with 1% Triton X-100, treated for 30 min with 0.06% H 2 0 2 in methanol to block endogenous peroxidase, rinsed 3 x 15 min in TBS with 1% Triton X-100, and incubated for 60 min with peroxidase-conjugated streptavidin (1
- Unstained brain cells from 28-day-old pig fetuses were analysed with flow cytometry directly after isolation (Fresh) or after 14 days in primaiy culture (Cultured) (Fig. 1).
- Plots A and B show the green and orange fluorescence of the cells.
- Histograms C and D show the frequency of cells as a function of their green fluorescence, and include identical markers (Ml) and the percentage of the total cell number present within the markers.
- Plot B shows regions set to define autofluorescent (Rl) and non- autofluorescent (R2) cell populations
- plots E and F show the size (forward scatter) and granularity (side scatter) of the autofluorescent (Rl) and non- autofluorescent (R2) cells.
- porcine fetal brain cells came out as a single population of cells without autofluorescence, while primary cultures of these cells, prepared to favour growth of astrocytes and macrophages/ rnicroglial cells, consisted of two cell populations: a larger population of non- autofluorescent cells and a smaller population of autofluorescent cells.
- the autofluorescent cells were more granular than the non-autofluorescent cells (Fig. 1).
- the isotype control (IC) IgGj is the negative control for the CD 18 and CD56 stainings
- the isotype control IgG 2a is the negative control for the CD44 and CD4 stainings.
- Cells were fixed and permeabilized prior to staining for GFAP.
- the GFAP control is a sample that received secondary antibody only. Regions were set in plots G and H to compare the GFAP staining of autofluorescent and non-autofluorescent cells.
- FIG. 3 Cultured brain cells isolated from 28-day-old pig fetuses were incubated with fluorescein-labelled E. coli (Fig. 3). The figure shows phagocytosis of E. coli.
- Plot A shows cells from a culture that received fluorescein-labelled E. coli (green fluorescence) 30 min prior to flow cytometry, while plot B shows cells from an untreated culture.
- the confocal laser microscopy image shows a cross section of a cell stained with the lipophilic and fluorescent Dil prior to incubation with fluorescein- labelled E. coli and dual-channel scanning.
- the red pseudocolour represents membranes and other lipids stained with Dil (rhodamine optical filter sets) and the yellow pseudocolour represents fluorescein-labelled E. coli (fluorescein optical filter sets). Scale bar: 10 ⁇ m.
- Flow cytometric analysis of brain-cell cultures incubated with fluorescein-labelled E. coli showed that the autofluorescent cell population split into two along the green-fluorescence axis of the dot plot, while the non-autofluorescent cell population remained as one (Fig. 3). When examined in a fluorescence microscope, the green fluorescence of the bacteria was not associated with the plasma membrane (not shown).
- confocal laser microscopy showed that the majority of the cells only were stained by Dil. Some cells had, however, fluorescent E. coli within cell borders (Fig. 3).
- Porcine fetal brain cells cultured under conditions that favour growth of astrocytes and macrophages/microglial cells (Castellano et al., 1991), consisted of both autofluorescent cells and non-autofluorescent cells, when analysed by flow cytometry.
- Autofluorescence is a known property of macrophages (Havenith et al., 1993; Nicod et al., 1989), and might be due to endogenous flavoproteins (Aubin et al., 1979; Benson et al., 1979), which are excitable by the 488-nm lasers used in this study, and can emit light in the green and orange ranges of the spectrum.
- the autofluorescent cells had high granularity, again typical of macrophages.
- the autofluorescent cells were macrophages.
- the autofluorescent cells were CD18TD44"CD56 ⁇ GFAP " , strongly suggesting that these cells indeed were macrophages or rnicroglial cells. Since no marker was available to distinguish between macrophages and rnicroglial cells, we refer to these cells as macrophages, as this is commonly done at this early stage of brain development (Perry et al., 1988).
- the non-autofluorescent cells were CD18 " CD44 " CD56 + GFAP + , suggesting that these cells were astrocytes.
- the autofluorescent cell population split into two along the green-fluorescence axis of the dot plot, and fluorescence microscopy and confocal laser microscopy revealed that the fluorescent bacteria were located within the cells, as strong evidence of phagocytic activity by the autofluorescent cells.
- fluorescence microscopy and confocal laser microscopy revealed that the fluorescent bacteria were located within the cells, as strong evidence of phagocytic activity by the autofluorescent cells.
- the autofluorescent cells were macrophages/microglial cells, while the non-autofluorescent cells were astrocytes.
- Example 2 Macrophages/microglial cells induce proliferation of human T lymphocytes, astrocytes do not
- Brain cells isolated from 28-day-old fetal pig brains were grown for 14 days in primary culture and flow sorted after staining with RPE-conjugated anti-CD56 (orange fluorescence) (Fig. 4).
- Allogeneic mononuclear blood cells (MBC; H-8053), sorted astrocytes, and sorted macrophages were ⁇ -irradiated (50 Gy) to halt their proliferation and mixed with lymphocytes from either of two human individuals (H-3970 and H-3977) (3 wells per combination). As a negative control, the lymphocytes were incubated without stimulators (12 wells per combination). The proliferative activity was determined by [ 3 H]thymidine incorporation after 4 days of co-culture. Bars represent means and standard enors of means.
- the proliferative activity of the lymphocytes was higher when co-cultured with sorted macrophages than when co-cultured with allogeneic mononuclear blood cells.
- the proliferative activity was slightly higher in wells with lymphocytes and astrocytes than in wells with lymphocytes only, but the difference was only statistically significant for one of the individuals.
- Pig embryonic VM cells including neurons, glia, and endothelial cells were analysed by flow cytometry for expression of ⁇ -galactosyl epitopes using biotinylated
- BS-IB4 Bandereia Simplicifolia isolectin B4 (BS-IB4) (Fig. 5A). A slight shift in fluorescence of less than one log was noted for the bulk population of bram cells when compared to the control. (FITC-conjugated avidin alone). This should be compared to BS-IB4 staining of PLMECs where a shift to the right on the logarithmic scale of at least two ten log steps was seen (Fig. 5B).
- Detection was accomplished by chemiluminescence and the two blots represent 5 and 10 second-exposures, respectively. Upon longer exposure times (> 10 seconds), we saw weak staining in the VM lane of a component of approximately 150 kDa size. Under these conditions, a component of similar size and staining intensity was seen among the ECV membrane proteins (Fig. 6).
- Fig. 7 shows a saggital section of the VM of a 27 day-old pig embryo stained immunohistochemically for tyrosine hydroxylase, which is the rate-limiting enzyme for dopamine production in dopaminergic neurons. Cell bodies and some axonal fibres are seen (Fig. 7A). Low power magnification of a coronal section of a 27 day-old pig embryo stained immunohistochemically using peroxidase-conjugated BS-IB4 isolectin (Fig. 7B). There is intense staining of embryonic brain microvascular endothelium (Fig. 7A).
- FIG. 7B a somewhat less intense staining of rnicroglial cells/tissue resident macrophages as seen at higher magnification
- Fig. 7C No prominent staining was found on neurons or glial cells. Staining of cells similar in morphology to the BS-IB4 stained cells in panel C, was seen with a mouse mAb specific for monocytes/tissue macrophages, which also binds porcine rnicroglial cells (Fig. 7D).
- VM membrane proteins which was of approximately the same intensity as the staining of ECV proteins, may be due to recognition of determinants related to ⁇ -Gal.
- isolectin-histochemistry indicated that the majority of the ⁇ -Gal expression is restricted to endothelial cells and rnicroglial cells/macrophages, and not to neurons and astrocytes, in fetal porcine brain tissue (Fig. 7).
- BS-IB4 reactivity in the adult mouse brain has also been shown to be confined to capillaries (Peters et al, 1979). Therefore, a more-likely explanation for the low-level expression in the Western blot experiments, is that the ⁇ -Gal expressing cells constitute only a small fraction of the total number of cells in the VM.
- Human IgG, IgM, and anti-Gal were purified from semm pooled from more than 20 healthy, blood type AB donors using beaded agarose with goat anti-human IgG (Fc specific; Sigma, USA), goat anti-human IgM ( ⁇ -chain specific; Sigma), or porcine thyroglobulin (source of ⁇ -galactosyl epitope; Sigma), respectively. Five ml of slurry (2.5 ml of packed beads) were poured into a column of 10 mm diameter and washed with PBS.
- the absorption at 280 nm was read spectrophotometrically, and contents of tubes containing protein were pooled, dialysed against 1% PBS, lyophilised, and resuspended in distilled water (1/100 of eluted volume).
- the protein concentration was determined using a BCA Protein Assay Reagent Kit (Pierce, USA) according to the manufacturer's instructions.
- the purity of the IgG and IgM preparations was analysed by SDS-PAGE: 4.0 ⁇ g of each sample was boiled in SDS reducing or non-reducing buffer for 5 min and loaded onto ready-made, 4-15% continuous gels (Bio-Rad, USA). After electrophoresis, the gels were stained using a silver-staining kit (Bio-Rad) according to the manufacturer's instructions. No IgM bands appeared in the IgG lanes, but weak IgG bands were present in the IgM lanes.
- the ⁇ -galactosyl-epitope reactivity of the antibodies purified from human semm using porcine thyroglobulin was assessed by incubating 5.
- the cells were washed once in PBS (250 g, 5 min), incubated with rabbit anti-human IgG F(ab') 2 FITC (1:10; DAKO, Denmark) or rabbit anti-human IgM F(ab') 2 FITC (1:10; DAKO) at 4°C for 60 min, washed twice in PBS (250 g, 5 min), and analysed by flow cytometry.
- the expression of the ⁇ -galactosyl epitope on Raji-GT cells was verified by staining Raji-GT cells and Raji cells with 3.0 ⁇ g FITC-conjugated BS-IB4. Transfection and selection of the Raji-GT cell line has been described by Kumagai-Biaesch et al. (1998).
- Example 5 Macrophages/microglial cells cultured from embryonic pig brain tissue express the ⁇ -galactosyl epitope
- Porcine embryonic brain cells were grown in primary culture with a high semm content in the medium, conditions which produce autofluorescent macrophages/ rnicroglial cells and non-autofluorescent astrocytes, as shown in Example 1.
- Cultured cells were analysed unstained and after staining with FITC-conjugated Bandereia Simplicifolia isolectin B4 (BS-IB4 FITC) by flow cytometry.
- the dotplots show the intensity of green (FL1) and orange (FL2) fluorescence (see Fig. 8), and contain a line that separates autofluorescent macrophages/microglial cells (m) from non-autofluorescent astrocytes (a).
- the ⁇ -galactosyl epitope expression may change when porcine tissue is cultured, but macrophages/microglial cells from embryonic pig brain maintained their ⁇ -galactosyl epitope expression in culture (Fig. 8).
- Example 6 Human semm and rabbit complement remove macrophages/microglial cells from cultured and freshly isolated porcine embryonic brain cells
- Dissociated brain tissue was split into aliquots, of which one was treated with human serum and rabbit complement prior to culture for 10 days, and another received an identical treatment after culture. These cells and untreated, cultured cells were analysed by flow cytometry without prior staining to compare the content of macrophages/microglial cells.
- the histograms show the cell frequency as a function of green-fluorescence intensity (FL1), and contain identical markers (Ml) to define the autofluorescent macrophages/microglial cells and the percentage of the cells that are within the markers. Both when applied to freshly isolated cells and to cells grown in primary culture, treatment with human semm and rabbit complement reduced the relative number of macrophages/microglial cells.
- Example 7 Treatment of porcine brain cells with anti-Gal and complement reduces the content of macrophages/microglial cells and their ability to induce human CD4 T- lymphocyte proliferation
- Raji cells (Raji) and Raji cells transfected to express porcine ⁇ l,3-galactosyl- transferase (and thus the ⁇ -galactosyl epitope; Raji-GT) were incubated with the antibodies against the ⁇ -galactosyl epitope (purified from normal semm as described in Example 4; in Fig. 10 refened to as aGal) or no antibodies and stained with either FITC-conjugated anti-human IgG (algG) or FITC-conjugated anti-human IgM (algM).
- the expression of the ⁇ -galactosyl epitope on Raji-GT cells was verified by staining these and Raji cells with FITC-conjugated BS-IB4.
- the purified antibodies contained both IgG and IgM reactive with Raji-GT cells, but not with Raji cells. Unspecific staining of Raji-GT cells by algG and algM was minimal, and the purified antibodies thus contained both IgG and IgM reactive with the ⁇ -galactosyl epitope (see Fig. 10).
- Porcine embryonic brain cells were grown in primary culture for 12 days, dissociated, and incubated with human IgG (circle in Fig. 11), human IgM (square in Fig. 11), human anti-Gal (triangle in Fig. 11), human semm (diamond in Fig. 11), or medium (filled circle in Fig. 11).
- Human IgG, IgM and anti-Gal were prepared as described in Example 4. After 60 min at 4°C, the cells were washed, resuspended in medium with rabbit complement, incubated at 37°C for 60 min, washed again, ⁇ -inadiated to halt their proliferation, and mixed with highly purified human peripheral blood CD4 T cells.
- CD4 T cells were also grown in absence of brain cells to determine their background proliferative activity (cross in Fig. 11). Proliferation was determined as incorporation of tritiated thymidine, and means of triplicate cultures are given in counts per minute (cpm) in Fig. 11. Bars represent one SEM. IgG and IgM reactive with the ⁇ -galactosyl epitope were present in the anti-Gal preparation (Fig. 10). The effect of the different brain-cell pretreatments on the content of macrophages/ rnicroglial cells and cell viability is given in Table 1 below.
- porcine embryonic brain cells treated with human IgG, human IgM, human anti-Gal, or human serum and rabbit complement did not induce proliferation of human CD4 T cells, while brain cells given a control treatment with medium and rabbit complement induced a significant proliferative response in human CD4 T cells (Fig. 11).
- Fig. 12 An in-vitro model was used to study the human CD4 T-cell response to porcine embryonic brain cells (Fig. 12).
- the bram cells were grown in primary culture prior to co-culture with human CD4 T cells, because only cultured cells, and not freshly isolated cells, will induce proliferation of human T cells (Brevig et al., 1997). Culturing under the conditions described herein, like intracerebral transplantation (Mason et al., 1986; Duan et al., 1995), upregulates the expression of MHC antigens (Brevig et al., 1999). Fig.
- Dissociated brain tissue from pig embryos contains neurons (N), astrocytes (A), macrophages/microglial cells (M), and endothelial cells (E).
- N neurons
- A astrocytes
- M macrophages/microglial cells
- E endothelial cells
- the latter two cell types express the ⁇ -galactosyl epitope ( ⁇ -Gal), and their removal prior to transplantation will greatly reduce the potential of the donor tissue to upregulate MHC antigens, particularly class II, once implanted.
- Primary culture in medium with a high semm content favours growth of astrocytes and macrophages, and upregulates the expression of MHC antigens.
- Dissociated porcine brain tissue cultured under these conditions can thus be used to study the human T-cell response to porcine neural xenografts in vitro.
- the approach of the inventors was (i) to target the ⁇ - galactosyl epitope, because it is expressed on macrophages/microglial cells, but not on neurons, in fresh porcine brain tissue (Sumitran et al., 1999), and (ii) to use antibody- and complement-mediated lysis, since even macrophages/microglial cells within small cell clusters can be removed by this mechanism.
- porcine aortic endothelial cells Pretreatment of dissociated porcine brain tissue with anti-Gal and complement probably also removes endothelial cells, because the ⁇ -galactosyl epitope is abundantly expressed on endothelial cells in embryonic pig brain (Sumitran et al., 1999), and porcine aortic endothelial cells are sensitive to lysis by anti-Gal and complement (Vaughan et al., 1994).
- porcine aortic endothelial cells constitutively express class I, but not class II, MHC antigens, and induce proliferation of human CD8, but not CD4, T cells (Murray et al, 1994).
- porcine aortic endothelial cells After culture with human tumour necrosis factor- ⁇ , which may be present in neural grafts due to surgically induced inflammation, porcine aortic endothelial cells also express MHC class II antigens and induce proliferation of human CD4 T cells (Batten et al., 1996). Removal of endothelial cells may thus be beneficial for the survival of neural xenografts, but it is not known whether donor-derived endothelial cells are necessary for xenograft neovascularization in humans.
- Example 8 Effects of the pretreatment on survival and function of porcine neural xenografts in rats
- C Dopaminergic cell bodies at high magnification (arrows).
- D Shows infiltration by host leukocytes (staining for CD45) around a vessel at the graft-host interface (arrow).
- Gr graft. Str, host striatum. Scale bars: 250 ⁇ m (A and B) and 25 ⁇ m (C and D).
- MHC class I antigens on porcine embryonic brain cells reduces the proliferative response of human CD8 T cells by about 50% in vitro (DerSimonian et al., 1999). MHC antigens are, however, not optimal targets for donor tissue pretreatments, because these molecules are present at very low levels in fresh brain tissue (Lampson, 1995) and upregulated after implantation (Widner et al.. 1988; Duan et al., 1995: Mason et al., 1986) (Fig. 12).
- pretreatment with anti-Gal and complement reduces the immunogenicity of porcine neural tissue.
- the pretreatment with anti-Gal and complement might be a valuable alternative or supplement to immunosuppression, and it can, unlike current immunosuppressive drugs, be expected to have no side effects.
- Barker R A Fricker R A, Abrous D N, Fawcett J, Dunnett S B (1995) A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplantation, Mar-Apr; 4(2): 173-200. Barker R A, Ratcliffe E, Mclaughlin M, Richards A, Dunnett S B (2000) J. Neurosci. 20:3415-3424. Bartlett P F, Rosenfeld J, Bailey K A, Cheesman H, Harvey A R, Ken R S (1990)
- Brevig T Pedersen E B, Kristensen T, Zimmer J (1997) Proliferative response of human T lymphocytes to porcine fetal brain cells. Cell Transplant 6:571-577. Brevig T, Kristensen T, Zimmer J (1999) Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain. Exp Neurol 159:474-483. Brevig T, Holgersson J, Widner H (2000) Trends Neurosci. (in press).
- Isacson O Breakefield X O (1997) Benefits and nsks of hostrng animal cells rn the human bram Nature Med 3 964-969 Isacson O, Deacon T W, Pakzaban P. Galpem W R, Dinsmore J, Bums L H (1995)
- Nicod L P Lipscomb M F, Toews G B, Weissler J C (1989) Separation of potent and poorly functional human lung accessoiy cells based on autofluorescence. J. Leukoc.
- Pakzaban P Deacon T W, Bums L H, Dinsmore J, Isacson O (1995) A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience 65:983-996. Pennell N A, Streit W J (1997) Colonization of neural allografts by host rnicroglial cells: relationship to graft neovascularization. Cell Transplant 6:221-230.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Prostheses (AREA)
Abstract
L'invention concerne un matériau de transplantation résultant de la dissociation de tissu porcin et de l'élimination de macrophages et/ou de microgliocytes dans ce tissu. Il peut s'agir de tissu nerveux embryonnaire ou foetal, et l'élimination peut s'effectuer par exposition de la préparation susmentionnée à des anticorps vis-à-vis de l'épitope Galα1-3Galβ1-R et à un réactif de complément. L'invention concerne par ailleurs l'utilisation de ce matériau de transplantation pour l'élaboration d'une préparation pharmaceutique utile dans la transplantation de tissu nerveux. L'invention concerne encore un kit comprenant une ou plusieurs enzymes propres à la dissociation tissulaire, une préparation d'anticorps et un réactif de complément. L'invention concerne enfin un procédé relatif à l'élimination des macrophages et/ou des microgliocytes dans un tissu nerveux embryonnaire ou foetal d'origine porcine, et un procédé relatif au traitement des troubles neurologiques par le biais de greffons porcins ainsi traités préalablement.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9903021 | 1999-08-26 | ||
SE9903021A SE9903021D0 (sv) | 1999-08-26 | 1999-08-26 | Reduction of the immunogenicity of non-human grafs |
PCT/SE2000/001648 WO2001013947A1 (fr) | 1999-08-26 | 2000-08-28 | Reduction de l'immunogenicite de greffons non humains |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1207903A1 true EP1207903A1 (fr) | 2002-05-29 |
Family
ID=20416763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00959076A Withdrawn EP1207903A1 (fr) | 1999-08-26 | 2000-08-28 | Reduction de l'immunogenicite de greffons non humains |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1207903A1 (fr) |
JP (1) | JP2003507131A (fr) |
AU (1) | AU774651B2 (fr) |
SE (1) | SE9903021D0 (fr) |
WO (1) | WO2001013947A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
EP3401682A1 (fr) * | 2017-05-09 | 2018-11-14 | Université de Nantes | Diagnostic, prévention et traitement de troubles de démyélinisation du système nerveux central |
CN109187958A (zh) * | 2018-09-12 | 2019-01-11 | 福建中医药大学附属人民医院(福建省人民医院) | 一种大鼠cd4抗体包被磁珠及其制备方法和应用以及含该磁珠的试剂盒 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2221234A1 (fr) * | 1995-05-15 | 1996-11-21 | Cedars-Sinai Medical Center | Composition et procede d'inhibition du rejet des greffons heterologues |
CA2220007A1 (fr) * | 1995-05-26 | 1996-11-28 | Diacrin, Inc. | Hepatocytes porcins a utiliser dans le traitement de troubles caracterises par une fonction hepatique insuffisante |
-
1999
- 1999-08-26 SE SE9903021A patent/SE9903021D0/xx unknown
-
2000
- 2000-08-28 JP JP2001518083A patent/JP2003507131A/ja active Pending
- 2000-08-28 AU AU70460/00A patent/AU774651B2/en not_active Ceased
- 2000-08-28 WO PCT/SE2000/001648 patent/WO2001013947A1/fr not_active Application Discontinuation
- 2000-08-28 EP EP00959076A patent/EP1207903A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0113947A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU774651B2 (en) | 2004-07-01 |
JP2003507131A (ja) | 2003-02-25 |
WO2001013947A1 (fr) | 2001-03-01 |
SE9903021D0 (sv) | 1999-08-26 |
AU7046000A (en) | 2001-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WALLGREN et al. | THE MAIN INFILTRATING CELL IN XENOGRAFT REJECTION IS A CD4+ MACROPHAGE AND NOT AT LYMPHOCYTE | |
DE60026166T2 (de) | Vetozellen die wirksam in der prävention von transplantatabstossung sind und kein graft-versus-host potential aufweisen | |
Lee et al. | Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. | |
KR100868235B1 (ko) | 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포 | |
US20010053362A1 (en) | Applications of immune system tolerance to treatment of various diseases | |
Wen et al. | Allo‐skin graft rejection, tumor rejection and natural killer activity in mice lacking p56lck | |
US20080124343A1 (en) | Treatment of Inappropriate Immune Responses | |
Sumitran et al. | Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non-Galα1, 3Gal-based xenoantigens | |
Schneider et al. | Pluripotent hemopoietic stem cells give rise to osteoclasts | |
AU774651B2 (en) | Reduction of the immunogenicity of non-human grafts | |
Brevig et al. | XENOTRANSPLANTATION FOR BRAIN REPAIR: Reduction of Porcine Donor Tissue Immunogenicity by Treatment with Anti-Gal Antibodies and Complement: 1 | |
JP2001139496A (ja) | 後天的免疫寛容の獲得方法 | |
Brevig et al. | Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain | |
Larsson et al. | Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1. 1 depletion | |
Galili et al. | Preparation of autologous leukemia and lymphoma vaccines expressing α-gal epitopes | |
Michalewicz et al. | Purification of adrenal chromaffin cells increases antinociceptive efficacy of xenotransplants without immunosuppression | |
US6953576B2 (en) | Method of modulating tumor immunity | |
FR2615737A1 (fr) | Preparation et utilisation d'interferon-gamma | |
WO2001089539A2 (fr) | Methodes de retablissement ou de stimulation de l'immuno-surveillance des cellules t suite a l'immunosupression induite par voie naturelle ou artificielle | |
KR100666607B1 (ko) | 이종의 cd4 t-세포 생산방법 및 이종의 cd4t-세포를 생산하는 동물모델 | |
CN113347991A (zh) | 用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合 | |
Boyd et al. | Interactions and quantitative analysis of immunoregulatory cells in the chicken thymus. | |
JP2647292B2 (ja) | 非ヒトキメラ哺乳動物 | |
JP2001512423A (ja) | 自然抗体抗原に対する寛容 | |
Brevig et al. | Neural xenotransplantation: pretreatment of porcine embryonic nigral tissue with anti-Gal antibodies and complement is not toxic for the dopaminergic neurons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20040331 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050908 |